Masterson, Stuart G., Lobel, Leslie, Carroll, Miles W., Wass, Mark N., Michaelis, Martin (2018) Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies. Frontiers in Immunology, 9 . ISSN 1664-3224. (doi:10.3389/fimmu.2018.01025) (KAR id:66962)
PDF
Publisher pdf
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/635kB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
PDF
Author's Accepted Manuscript
Language: English
This work is licensed under a Creative Commons Attribution 4.0 International License.
|
|
Download this file (PDF/336kB) |
Preview |
Request a format suitable for use with assistive technology e.g. a screenreader | |
Official URL: https://doi.org/10.3389/fimmu.2018.01025 |
Abstract
The recent West African Ebola virus pandemic, which affected >28,000 individuals increased interest in anti-Ebolavirus vaccination programs. Here, we systematically analyzed the requirements for a prophylactic vaccination program based on the basic reproductive number (R0, i.e. the number of secondary cases that result from an individual infection). Published R0 values were determined by systematic literature research and ranged from 0.37 to 20. R0s ?4 realistically reflected the critical early outbreak phases and superspreading events. Based on the R0, the herd immunity threshold (Ic) was calculated using the equation Ic=1–(1/R0). The critical vaccination coverage (Vc) needed to provide herd immunity was determined by including the vaccine effectiveness (E) using the equation Vc=Ic/E. At an R0 of 4, the Ic is 75% and at an E of 90%, more than 80% of a population need to be vaccinated to establish herd immunity. Such vaccination rates are currently unrealistic because of resistance against vaccinations, financial/ logistical challenges, and a lack of vaccines that provide long-term protection against all human-pathogenic Ebolaviruses. Hence, outbreak management will for the foreseeable future depend on surveillance and case isolation. Clinical vaccine candidates are only available for Ebola viruses. Their use will need to be focused on health care workers, potentially in combination with ring vaccination approaches.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.3389/fimmu.2018.01025 |
Subjects: |
Q Science > QR Microbiology Q Science > QR Microbiology > QR180 Immunology Q Science > QR Microbiology > QR355 Virology |
Divisions: | Divisions > Division of Natural Sciences > Biosciences |
Depositing User: | Martin Michaelis |
Date Deposited: | 09 May 2018 12:31 UTC |
Last Modified: | 05 Nov 2024 11:06 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/66962 (The current URI for this page, for reference purposes) |
- Link to SensusAccess
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):